Adam Feuerstein Launches Biotech Newsletter – STAT’s Biotech Scorecard
Adam Feuerstein, a senior writer and biotech columnist for STAT, has launched a weekly email newsletter called Adam’s Biotech Scorecard. The newsletter, exclusive to STAT+ subscribers, began distribution on March 28, 2026, and aims to provide unfiltered analysis at the intersection of Wall Street and biotechnology.
About Adam Feuerstein
Feuerstein is a veteran reporter with decades of experience covering the biotech industry. He also serves as a co-host of STAT’s weekly “The Readout LOUD” podcast . Readers can reach him on Signal at stataf.54 .
What to Expect from Adam’s Biotech Scorecard
Subscribers to Adam’s Biotech Scorecard can anticipate:
- Unfiltered and uncompromising insights into the biotech sector.
- Analysis of the interplay between drug development, business, and Wall Street.
- A reader mailbag section.
- Occasional personal updates, including pictures of Feuerstein’s dog.
Subscription Information
Adam’s Biotech Scorecard is free for current STAT+ subscribers. New subscribers can access the newsletter through various STAT+ plans . Those without a STAT+ subscription can sign up for individual or group plans to gain access .
The Value of Independent Analysis
Feuerstein’s newsletter promises a unique perspective, offering a scorecard-style analysis of the biotech landscape. This aims to provide subscribers with valuable, and potentially challenging, insights into the industry.